Hims & Hers (HIMS) - Pangali EV/EBITDA

Can a D2C pharmacy with a subscription model ensure endless growth? The current EV/EBITDA multiple of Hims & Hers Health provides the answer, and this parameter currently stands at 83.79. The digital ecosystem of Hims & Hers Health automates access to treatment in the US and UK, while minimal geopolitical risks are mitigated through the rapid rotation of raw material suppliers from Asia.

Investors are assessing the resilience of Hims & Hers Health (HIMS) through the lens of its dependence on external manufacturers and contractors. While this model minimizes capital expenditures, it renders operational efficiency a key driver of valuation. By analyzing the historical EV/EBITDA trajectory, we are benchmarking the total enterprise value against earnings before interest, taxes, depreciation, and amortization. A decline in this multiple signals that the asset is undervalued and creates an attractive entry point.